EV Biologics, Inc. (YECO)
USD 0.09
(-0.12%)
USD 0.09
(-0.12%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.26 Million USD | 93.98% |
| 2022 | -21.05 Million USD | -5330.79% |
| 2021 | -387.69 Thousand USD | -291.77% |
| 2020 | -98.96 Thousand USD | -0.57% |
| 2019 | -98.4 Thousand USD | 0.0% |
| 2017 | -551.58 Thousand USD | 98.96% |
| 2016 | -53.19 Million USD | -712.82% |
| 2015 | 8.67 Million USD | -18.82% |
| 2014 | 10.69 Million USD | 6.4% |
| 2013 | 10.04 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 85.42 Thousand USD | 144.6% |
| 2024 Q2 | -191.54 Thousand USD | 3.11% |
| 2024 Q1 | -197.69 Thousand USD | 16.13% |
| 2023 FY | -1.26 Million USD | 93.98% |
| 2023 Q2 | -182.68 Thousand USD | 23.96% |
| 2023 Q4 | -235.7 Thousand USD | 37.63% |
| 2023 Q3 | -377.91 Thousand USD | -106.86% |
| 2023 Q1 | -240.23 Thousand USD | 97.83% |
| 2022 Q3 | -9.21 Million USD | -3412.93% |
| 2022 FY | -21.05 Million USD | -5330.79% |
| 2022 Q2 | -262.41 Thousand USD | 0.0% |
| 2022 Q4 | -11.09 Million USD | -20.35% |
| 2021 Q2 | -86.05 Thousand USD | 45.29% |
| 2021 FY | -387.69 Thousand USD | -291.77% |
| 2021 Q3 | -360.91 Thousand USD | -319.42% |
| 2021 Q1 | -157.29 Thousand USD | 0.0% |
| 2020 FY | -98.96 Thousand USD | -0.57% |
| 2019 FY | -98.4 Thousand USD | 0.0% |
| 2017 FY | -551.58 Thousand USD | 98.96% |
| 2017 Q4 | -2.23 Million USD | 0.0% |
| 2017 Q2 | -1.17 Million USD | 0.0% |
| 2017 Q1 | -1.17 Million USD | 47.46% |
| 2016 FY | -53.19 Million USD | -712.82% |
| 2016 Q4 | -2.23 Million USD | 21.14% |
| 2016 Q3 | -2.83 Million USD | 95.38% |
| 2016 Q2 | -61.41 Million USD | -2512.59% |
| 2016 Q1 | 2.54 Million USD | 21.43% |
| 2015 Q1 | 2.04 Million USD | 13.03% |
| 2015 Q4 | 2.09 Million USD | -41.46% |
| 2015 Q3 | 3.58 Million USD | 44.79% |
| 2015 FY | 8.67 Million USD | -18.82% |
| 2015 Q2 | 2.47 Million USD | 20.79% |
| 2014 Q4 | 1.81 Million USD | -22.84% |
| 2014 Q1 | 2.7 Million USD | 17.7% |
| 2014 Q2 | 3.15 Million USD | 16.75% |
| 2014 Q3 | 2.34 Million USD | -25.66% |
| 2014 FY | 10.69 Million USD | 6.4% |
| 2013 Q2 | 2.29 Million USD | 3.79% |
| 2013 Q1 | 2.21 Million USD | -19.9% |
| 2013 Q3 | 2.53 Million USD | 10.03% |
| 2013 FY | 10.04 Million USD | 0.0% |
| 2013 Q4 | 2.29 Million USD | -9.18% |
| 2012 Q4 | 2.76 Million USD | 99900.0% |
| 2012 Q3 | 2766.74 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 5.114% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 81.854% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 102.392% |
| Nascent Biotech, Inc. | -2.08 Million USD | 39.304% |
| Rebus Holdings, Inc. | -1.02 Million USD | -24.229% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 101.945% |
| Qrons Inc. | -789.34 Thousand USD | -60.529% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -100.367% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 97.976% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -204.981% |
| Skye Bioscience, Inc. | -37.64 Million USD | 96.634% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 98.31% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 80.731% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -363.469% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.405% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 56.191% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 30.397% |
| Mesoblast Limited | -87.95 Million USD | 98.559% |
| Marizyme, Inc. | -65.34 Million USD | 98.061% |
| Genus plc | 7.9 Million USD | 116.04% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 88.366% |
| Pharming Group N.V. | -10.54 Million USD | 87.987% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 41.602% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 65.848% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 85.672% |
| ContraFect Corporation | -65.15 Million USD | 98.055% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 74.066% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 26.647% |
| IMV Inc. | -36.48 Million USD | 96.527% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 84.278% |
| MultiCell Technologies, Inc. | -380.07 USD | -333294.901% |
| ONE Bio Corp. | 8.67 Million USD | 114.604% |
| Accustem Sciences Inc. | -3.74 Million USD | 66.177% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 97.549% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Q BioMed Inc. | -2.05 Million USD | 38.252% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 66.056% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 46.779% |
| Biomind Labs Inc. | -1.21 Million USD | -4.349% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 97.878% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 59.148% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 83.967% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 34.994% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -8361.098% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 92.016% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 78.218% |
| GB Sciences, Inc. | -1.36 Million USD | 6.943% |
| Alpha Cognition Inc. | -13.77 Million USD | 90.8% |
| HST Global, Inc. | -146.21 Thousand USD | -766.653% |
| CSL Limited | 2.64 Billion USD | 100.048% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 27.789% |
| Halberd Corporation | -79.67 Thousand USD | -1490.358% |
| Enzolytics Inc. | -2.17 Million USD | 41.79% |
| Agentix Corp. | -1.37 Million USD | 7.792% |
| Resverlogix Corp. | -3.61 Million USD | 64.899% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 60.045% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.571% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1392.994% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 118.299% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 68.106% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 58.127% |
| AVAX Technologies, Inc. | -6.41 Million USD | 80.243% |
| Zenith Capital Corp. | -10.59 Million USD | 88.041% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.673% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -5351.915% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 69.437% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -1996.494% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 36.805% |
| Kadimastem Ltd | -3.3 Million USD | 61.688% |
| Helix BioMedix, Inc. | -1.05 Million USD | -19.987% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 66.82% |
| BioStem Technologies, Inc. | -8.48 Million USD | 85.063% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -187.092% |
| LadRx Corporation | 400.44 Thousand USD | 416.433% |
| Cell Source, Inc. | -5.32 Million USD | 76.187% |
| Regen BioPharma, Inc. | 1.02 Million USD | 223.803% |
| Regen BioPharma, Inc. | 1.02 Million USD | 223.803% |
| NovAccess Global Inc. | -4.76 Million USD | 73.431% |
| Affymax, Inc. | -14.42 Million USD | 91.215% |
| Itoco Inc. | -1.86 Million USD | 32.202% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 71.477% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 24.078% |
| Mobile Lads Corp. | -2.26 Million USD | 44.014% |
| CytoDyn Inc. | -49.84 Million USD | 97.458% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1503.297% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -455.451% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -34.583% |
| SYBLEU INC | -180.3 Thousand USD | -602.776% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 21.43% |
| International Stem Cell Corporation | -131 Thousand USD | -867.278% |
| Bioxytran, Inc. | -4.28 Million USD | 70.394% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2234.784% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 49.921% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 97.364% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 40.06% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -62.269% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 60.002% |
| Neutra Corp. | -233.46 Thousand USD | -442.751% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 93.755% |
| PureTech Health plc | -65.69 Million USD | 98.071% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 94.042% |
| IXICO plc | -1.17 Million USD | -7.567% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 87.235% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.782% |
| CSL Limited | 2.64 Billion USD | 100.048% |
| Cellectis S.A. | -103.17 Million USD | 98.772% |